Surgical robotics in China has moved from early imported systems (Intuitive’s da Vinci dominated the market through the 2010s) to a diverse domestic field, accelerated by NMPA Class III approvals in the 2020s. The segment now spans general laparoscopic platforms (Toumai, MicroHand, Kangduo, Shurui’s single-port systems), orthopedic navigation and cutting robots (Tinavi, Hurwa, Kinguide), neurosurgical systems (Remebot, Sinovation, Uigsbrain), vascular interventional robots for PCI and neuro/peripheral procedures (R-ONE, ETcath, ALLVAS, Jieruo, Hanglok), and specialty platforms for ophthalmology, urology, and oral surgery.
Three structural factors shape the Chinese surgical robotics market: the NMPA’s expedited innovative device review pathway which compressed approval timelines, domestic reimbursement coverage expansion in leading cities, and DRG/DIP payment reform favoring hospitals that invest in efficiency-boosting systems. For international manufacturers, market entry requires navigating NMPA registration (typically 18–24 months for Class III), domestic clinical trials, and localized post-market surveillance requirements.
The listing below reflects products documented in this database at this snapshot — not a complete industry inventory. See data methodology for how this list is compiled and maintained.